(Q33500786)

27 July 2017

1 reference

title

Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based? (English)

1 reference

27 July 2017

4

Sandro Barni

1 reference

27 July 2017

1

Fausto Petrelli

1 reference

27 July 2017

2

Mary Cabiddu

1 reference

27 July 2017

3

Mara Ghilardi

1 reference

27 July 2017

language of work or name

English

0 references

publication date

1 October 2009

1 reference

Expert Opinion on Investigational Drugs

27 July 2017

published in

1 reference

27 July 2017

volume

18

1 reference

27 July 2017

issue

10

1 reference

27 July 2017

page(s)

1467-1477

1 reference

Molecular portraits of human breast tumours

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

Molecular portraits of breast cancer: tumour subtypes as distinct disease entities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

How basal are triple-negative breast cancers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

Triple-negative breast cancer: therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

An immunohistochemical study of the breast using antibodies to basal and luminal keratins, alpha-smooth muscle actin, vimentin, collagen IV and laminin. Part I: Normal breast and benign proliferative lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

Expression of smooth muscle-specific proteins in myoepithelium and stromal myofibroblasts of normal and malignant human breast tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

Immunoreactivity of ductal cells with putative myoepithelial markers: A potential pitfall in breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

Gene expression patterns associated with p53 status in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

BRCA1, a potential predictive biomarker in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

Triple-negative breast cancer: clinical features and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

The role of BRCA1 in the cellular response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

Platinum-based chemotherapy in triple-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

Genome maintenance mechanisms for preventing cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

Targeting Src in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903222268

10.1517/13543780903222268

21 January 2018

Identifiers

DOI

1 reference

27 July 2017

1 reference